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We screened serum samples referred to the national refer-
ence laboratory in Guatemala that were positive for chikun-
gunya or dengue viruses in June 2015. Co-infection with 
both viruses was detected by reverse transcription PCR in 
46 (32%) of 144 samples. Specimens should be tested for 
both arboviruses to detect co-infections.
Chikungunya virus (CHIKV) and dengue virus (DENV) are arboviruses currently circulating in Southeast Asia, 
Central and West Africa, the Pacific islands, and the Ameri-
cas, and their transmission can occur simultaneously (1). 
DENV and CHIKV co-infections have been reported from 
13 of 98 countries/territories to which the viruses are en-
demic and are more likely to occur in areas with high trans-
mission intensity. Co-infection rates reported have ranged 
from 2% in Gabon to 34% in Nigeria (1–3).
The Americas are currently experiencing an unprec-
edented number of DENV infections that coincided with 
emergence of CHIKV infections. A total of 2.3 million 
DENV infections and 635,000 CHIKV infections were re-
ported in this region in 2015 (4,5). However, details of the 
frequency of co-infection are lacking (1), although a recent 
study involving 173 samples from Nicaragua that were pos-
itive for either virus found a co-infection rate of 22% (6).
Co-infections might be frequently missed by surveil-
lance systems because Pan American Health Organization 
(PAHO) diagnostic algorithms indicate that DENV-posi-
tive samples do not need to be tested for CHIKV or other 
viruses and vice versa (7). The clinical role of co-infec-
tion is somewhat disputed because some (8) but not all 
(1,9) studies reported an association between co-infection 
and disease severity for symptoms such as diarrhea (9) 
or hemorrhage (10).
Although Guatemala has had constant dengue trans-
mission for >20 years (11), the first cases of CHIKV in-
fection were reported in September 2014. We report the 
proportion of patients co-infected with DENV and CHIKV 
and the association of co-infection with disease sever-
ity among patients referred for diagnosis to the National 
Health Laboratory (NHL) in Guatemala City, Guatemala, 
in June 2015. Because Zika virus was not introduced until 
November 2015, we did not test for this virus in this study.
The Study
Serum samples from febrile persons suspected of having 
arboviral infections are referred to the NHL in Guatemala 
for surveillance and confirmation purposes. For logistical 
reasons, most samples are received from 12 of the 22 dis-
tricts in Guatemala, and most samples originate from Quet-
zaltenango, Guatemala, and Escuintla Districts, the largest 
urban centers in Guatemala.
We selected for screening a convenience set of con-
secutive samples received in June 2015, which is the peak 
transmission season for DENV, and reported as having 
positive results by reverse transcription PCR (RT-PCR) for 
either virus. Clinical data for patients were obtained from 
surveillance databases to compare patients with monoin-
fections or coinfections with DENV or CHIKV. All sam-
ples were obtained from patients <5 days of symptom on-
set. Samples were obtained after patients provided consent 
and donated to laboratories for further testing. All samples 
were anonymous. Results of the study were not used for 
clinical management or surveillance purposes.
During June 2015, a total of 523 samples were test-
ed for CHIKV at the NHL; 328 (63%) were positive for 
CHIKV RNA by RT-PCR. A total of 514 samples were 
also tested by RT-PCR for DENV; 75 (9%) were posi-
tive (Figure). Seventy-four of samples reported as positive 
for DENV RNA and 70 samples reported as positive for 
CHIKV RNA were available for further screening for the 
other virus.
Samples selected were consecutive positive samples 
from the beginning of the month; there were no addition-
al exclusion or inclusion criteria. We included as many 
samples as possible within the time available. RNA was 
extracted by using a Viral RNA Mini Kit (QIAGEN, Man-
chester, UK) and tested by using the US Centers for Dis-
ease Control (CDC; (Atlanta, GA, USA) multiplex DENV 
RT-PCR and the CDC CHIKV 6856F/6981c/6919-FAM 
RT-PCR (12).
Twenty-five (33.8%) of 74 DENV-positive samples 
were positive for CHIKV, and 21 (30%) of 70 CHIKV- 
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positive samples were positive for DENV RNA. Co-infection 
with CHIKV was detected in 4/9 samples containing 
DENV-1, 40/76 samples containing DENV-2, 0/3 samples 
containing DENV-3 and 2/7 samples containing DENV-4.
Clinical characteristics of patients with CHIKV and 
DENV monoinfections and co-infections were similar 
(Table). Patients co-infected with CHIKV and DENV were 
more likely to have a rash than those with DENV monoin-
fections (p = 0.02) and were more likely to be hospitalized 
than those with CHIKV monoinfections (p = 0.002). All 
other associations were not statistically significant.
Conclusions
Our findings must be viewed with caution because of the lim-
itations of this study. The study was not powered to analyze 
clinical associations with a high robustness because of the 
small number (n = 46) of co-infected samples tested. Also, 
because samples were selected at a reference laboratory 
and only symptomatic cases were tested, the prevalence of 
co-infection might be different in a less selected population.
The PAHO algorithm recommends screening clinical 
specimens by using consecutive assays and ending screen-
ing once a pathogen is identified. CDC in turn recommends 
simultaneously conducting RT-PCRs for DENV, CHIKV, 
and Zika virus. Emergence of Zika virus in Latin America 
has further complicated diagnosis of arboviral infections, 
and simultaneous co-infections with all 3 arboviruses have 
been reported (13). Although the PAHO approach misses 
co-infections, the CDC approach is costlier.
Guatemala used the PAHO algorithm because of a 
shortage of consumable supplies. On further testing, 25 
(33.8%) of 74 DENV-positive samples were positive for 
CHIKV, and 21 (30%) of 70 CHIKV-positive samples were 
positive for DENV. Because Guatemala reported 49,043 
cases of DENV and CHIKV infections in 2015, it is likely 
that the algorithm missed a large number of co-infections. 
2004 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No.11, November 2016
Figure. Positivity of samples tested for A) dengue virus and B) chikungunya virus, Guatemala, 2015.
 
 
 
Table. Characteristics of patients infected with chikungunya virus, dengue virus, or both, Guatemala, 2015* 
Characteristic 
CHIKV 
moninfection 
DENV 
monoinfection 
DENV/CHIKV 
co-infection 
p value 
CHIKV vs co-infection DENV vs co-infection 
No. samples tested 49 49 46 
 
 
Sex      
 M 15/48 (31) 23/45 (51) 21/46 (46) 0.2 0.6 
 F 33/48 (69) 22/45 (49) 25/46 (54) 0.2 0.6 
Age, y 
 
 
 
  
 <1 2/48 (4.2) 3/45 (7) 5/46 (11) 0.2 0.7 
 2–16 15/48 (31) 26/45 (58) 19/46 (41) 0.4 0.1 
 17–30 13/48 (27) 6/45 (13) 9/46 (20) 0.4 0.5 
 31–60 14/48 (29) 9/45 (20) 10/46 (22) 0.5 1 
 >60 4/48 (8.3) 1/45 (2) 3/46 (7) 1 0.6 
Sign/symptom 
 
 
 
  
 Hemorrhage 7/49 (14) 11/44 (25) 8/44 (18) 0.8 0.6 
 Arthralgia/myalgia 41/44 (93) 36/42 (86) 35/45 (77) 0.07 0.4 
 Fever 43/48 (90) 41/42 (98) 46/46 (100) 0.06 0.5 
 Rash 31/48 (65) 11/43 (26) 23/44 (52) 0.3 0.02 
 Nausea 26/46 (57) 31/44 (70) 22/44 (50) 0.7 0.08 
 Vomiting 13/46 (28) 21/43 (49) 16/45 (36) 0.5 0.3 
 Diarrhea 3/18 (17) 10/34 (29) 6/25 (24) 0.7 0.8 
 Headache 40/47 (85) 35/42 (83) 40/44 (91) 0.5 0.3 
 Hospitalization 0/48 (0) 16/45 (36) 8/46 (17) 0.002 0.09 
 Death 0/48 (0) 4/45 (9) 2/46 (4) 0.2 0.4 
*Values are no. positive/no. tested (%) unless otherwise indicated. CHIKV, chikungunya virus; DENV, dengue virus. 
 
Co-infections with Chikungunya and Dengue Viruses
Patients with single and dual infections had similar clinical 
manifestations in this limited study.
The frequency of arbovirus coinfections in Guatemala 
is high. Simultaneous screening for DENV, CHIKV, and 
Zika virus in disease-endemic areas would improve the 
quality of arboviral surveillance and potentially aid in clini-
cal management of the disease.
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